Follicular lymphoma: Difference between revisions

	Follicular lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Follicular lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT scan
MRI
Echocardiography or Ultrasound
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Follicular lymphoma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Follicular lymphoma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Follicular lymphoma
CDC on Follicular lymphoma
Follicular lymphoma in the news
Blogs on Follicular lymphoma
Directions to Hospitals Treating Follicular lymphoma
Risk calculators and risk factors for Follicular lymphoma

Revision as of 16:31, 21 September 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

@@ Line 22: / Line 22: @@
 ==Treatment==
-There is no consensus regarding the best treatment [[algorithm]], but watch-and-wait policies, [[alkylators]], [[anthracycline]]-containing regimens (eg. [[CHOP]]), [[rituximab]], [[autologous]] and [[allogenic]] [[hematopoietic stem cell transplantation]] have all been applied. The disease is regarded as incurable (although allogenic stem cell transplantation may be curative, the [[death|mortality]] from the procedure is too high to be a first line option). The exception is localized disease, which can be cured by local [[irradiation]]. The typical pattern is one of good responses from treatment, followed by relapses some years later. [[Median]] survival is around 10 years, but the range is wide, from less than one year, to more than 20 years. Some patients may never need treatment.
 ==References==

v t e Myeloid Hematological malignancy/leukemia histology (ICD-O 9590-9989, C81-C96, 200-208)
CFU-GM/ and other granulocytes	Template:Navbox subgroup
MEP	Template:Navbox subgroup
CFU-Mast	Mastocytoma (Mast cell leukemia, Mast cell sarcoma, Systemic mastocytosis)
Multiple/unknown	AML (Acute panmyelosis with myelofibrosis, Myeloid sarcoma) · MP (Myelofibrosis) · Acute biphenotypic leukaemia
See also hematology, lymphoid malignancy